Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Points - Castle Biosciences, Inc. granted restricted stock units (RSUs) to 66 employees, covering a total of 135,978 shares of common stock as part of their employment inducement [1] - The RSUs will vest over a four-year period, with 25% vesting on the first anniversary and the remaining shares vesting annually in three equal installments, contingent on continued service [2] - Castle Biosciences focuses on innovative diagnostic tests that guide patient care, with a portfolio that includes tests for skin cancers, Barrett's esophagus, and uveal melanoma [3][4] Company Overview - Castle Biosciences aims to transform disease management by prioritizing patients, clinicians, employees, and investors [3] - The company is actively engaged in research and development for tests addressing high clinical needs, including a test for guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis [4]